Clinical Trial Update: LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 results for LDK378 (alectinib) in adult Chinese patients with ALK-rearranged advanced non-small cell lung cancer who were previously treated with criz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-01-17